Bio-Techne Corp at JPMorgan Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Great. Thank you, Chuck. That was a great overview. Let me start by asking on your COVID products, the serology test. Can you remind us how your test is differentiated from other serology tests in the market? And since we're seeing some TCR-based tests being introduced in the market as well, can you also talk about how your serology test is stacked against the TCR tests?

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : I was -- T cell receptor based, the T cell sequencing.

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : What about your commercialization strategy? I mean since your test is quantitative, are you going to partner with biopharma in the vaccine trials? Or are you just going to market it directly?

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Got it. Other than COVID products, can you talk about which parts of your base business has seen the greatest headwinds or tailwinds from COVID? And given the recent resurgence in cases, are you seeing any incremental impact?

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Incremental headwinds and tailwinds.

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Sure. Sure. That's great. For the kidney rejection test, when might we expect to see initial data on the test? And then for the exosome test in general, besides prostate and kidney, what other potential indications do you think you can beat the ctDNA based test with an exosome approach?

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Great. And lastly, with all the interest around unbiased proteomics these days, what are your thoughts around more participation in HiPlex or even unbiased proteomics?

Question: Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst : Right. Well, that's all the time we had. Thanks so much for the great overview, and enjoy the rest of conference.